올리패스

244460KOSDAQ기초 의약물질 제조업

32.0 / 100

Reference Date: 2026-06-10

Financial Score10.5 / 40

News Sentiment7.5 / 25

Momentum10.0 / 20

Disclosure4.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

OliPass is a biotech company developing RNA therapeutics using its proprietary OPNA platform, which targets pre-mRNA to inhibit disease-causing proteins with high precision. The company is advancing pipeline programs such as OLP-1002, a non-opioid pain reliever targeting the SCN9A gene, leveraging its platform's advantages over traditional RNA therapies. Its business model includes licensing technology to pharmaceutical partners and collaborative R&D for new drug development.

Number of Employees

26people

Average Salary

51.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

7.89Industry Average 1.740.0Point

4.5x industry avg (risky)

ROE

-226.92Industry Average -6.033.5Point

37.6x industry avg (excellent)

Debt Ratio

63.41Industry Average 6.620.0Point

9.6x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼38.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲26.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -174.3% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 0Negative 2Average Sentiment Score 30

Negative
올리패스, 회생절차 개시 결정
올리패스의 회생절차 개시 결정으로 인해 기업 재무상태 악화 우려가 제기됨.
Negative
올리패스, 1분기 매출 9257만원…상장적격성 실질심사 사유 추가
올패스의 분기 매출이 상장 기준 미달로 인해 영업 정지 가능성이 제기되어 부정적 영향이 예상됩니다.

Detailed Momentum

52-week position4.0Point

52w mid range (50%)

Current 1,651Won52-week high 1,65152-week low 1,651

1-month return3.0Point

1m 0% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

10 totalPositive 0Neutral 8Negative 2

Negative기타시장안내 (회생절차 개시결정 관련 시장안내)2026-06-05
Negative회생절차개시결정2026-06-05
Neutral[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)2026-06-01
Neutral[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)2026-06-01
Neutral[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)2026-06-01